Kardi AI Is Scaling, MDR Class IIa Certified and Series A Ready

Why It Matters

The certification removes a major regulatory barrier, enabling rapid European scale‑up, while the clinical data demonstrates a tangible improvement in arrhythmia detection and potential cost savings for hospitals.

Key Takeaways

• Extends ECG monitoring to up to 12 months
• MDR Class IIa certification achieved EU-wide
• 300+ serious cardiac cases detected in Czech pilots
• Detection rate 30%, six times Holter monitoring
• German rollout Q4 2026 planned; Series A funding imminent

Pulse Analysis

Short‑term Holter recordings capture only a fraction of intermittent arrhythmias, leaving many patients undiagnosed. Kardi Ai tackles this diagnostic blind spot by offering chest‑strap devices that record ECG continuously for three, six or twelve months, feeding raw waveforms into a cloud‑based AI engine. The models flag rhythm abnormalities and generate physician‑ready reports within five minutes, compressing a typical four‑to‑five‑week turnaround to near real‑time. Securing EU MDR Class IIa status in October 2025 removes the primary regulatory hurdle, positioning the solution for rapid cross‑border deployment across Europe. This approach aligns with emerging value‑based care models that reward early detection.

In the Czech Republic, Kardi Ai is already active in 40 hospitals, serving roughly 15 % of the nation’s cardiologists and more than 3,500 patients. Two local insurers reimburse the service, turning a pilot into a sustainable revenue stream. To date the platform has logged over 10,000 clinical findings, including more than 300 confirmed serious rhythm disorders—most notably atrial fibrillation detected in 27 % of post‑stroke patients during a three‑month wear period. By delivering diagnostic reports in minutes, the AI layer eases cardiologists’ workload, allowing them to focus on treatment decisions rather than data triage.

The company’s next milestone is a German rollout slated for Q4 2026, a market where procurement cycles are longer and data‑governance scrutiny is intense. Kardi Ai’s participation in the health.tech | global summit and the CEE Health & Medtech Reception puts it directly in front of Series A investors and DACH hospital decision‑makers, accelerating fundraising and partnership talks. If the Czech reimbursement model can be replicated, the firm could secure multi‑year contracts across the DACH region, delivering a scalable revenue engine while addressing a clear clinical need. Success will hinge on seamless integration with existing cardiology IT stacks and transparent AI oversight.